Stemline Therapeutics, Inc. (STML)' SL-401 Receives Orphan Drug Designation for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
6/10/2013 9:26:20 AM
More...
|
Stemline Therapeutics, Inc. (STML) to Present at the Jefferies and Co. 2013 Global Healthcare Conference
5/31/2013 10:11:22 AM
More...
|
Stemline Therapeutics, Inc. (STML) Announces Presentations at the 2013 American Society of Clinical Oncology Annual Meeting
5/30/2013 9:38:48 AM
More...
|
Stemline Therapeutics, Inc. (STML) Announces Exercise of Option to Purchase Additional Shares
5/23/2013 9:48:53 AM
More...
|
Stemline Therapeutics, Inc. (STML) Announces Closing of $60 Million Public Offering of Common Stock
5/22/2013 9:44:58 AM
More...
|
Stemline Therapeutics, Inc. (STML) Prices $60 Million Public Offering of Common Stock
5/17/2013 9:17:34 AM
More...
|
Stemline Therapeutics, Inc. (STML) to Present at the 12th Annual Needham Healthcare Conference on May 1, 2013
4/25/2013 1:31:40 PM
More...
|
Stemline Therapeutics, Inc. (STML) to Present at the 25th Annual Roth Conference on March 20, 2013
3/12/2013 12:51:36 PM
More...
|
Stemline Therapeutics, Inc. (STML) to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
2/27/2013 1:29:16 PM
More...
|
Stemline Therapeutics, Inc. (STML) to Present at Leerink Swann and Company Global Healthcare Conference
2/12/2013 10:23:55 AM
More...
|
|